Ftse Mib
33.739,90
-0,08%
DAX
19.848,77
-0,34%
S&P 500
5.974,07
0,73%
NASDAQ
19.764,89
0,98%
Bitcoin
93.975,10
-0,76%
Pepperstone
Advertisement
Registration Strip Icon for charts Registrati per grafici in tempo reale, strumenti di analisi e prezzi.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Tenax Therapeutics Inc (TENX) Tenax Therapeutics Inc (TENX) Notizie

TENX

Tenax Therapeutics (TENX)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:TENX
DataOraFonteTitoloSimboloCompagnia
13/12/202402:09Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:TENXTenax Therapeutics Inc
06/12/202422:54Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:TENXTenax Therapeutics Inc
05/12/202419:47Edgar (US Regulatory)Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain InvestorsNASDAQ:TENXTenax Therapeutics Inc
04/12/202423:16Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:TENXTenax Therapeutics Inc
26/11/202422:30Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:TENXTenax Therapeutics Inc
15/11/202401:14Edgar (US Regulatory)Form SC 13G - Statement of Beneficial Ownership by Certain InvestorsNASDAQ:TENXTenax Therapeutics Inc
14/11/202418:39Edgar (US Regulatory)Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:TENXTenax Therapeutics Inc
13/11/202422:04Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:TENXTenax Therapeutics Inc
31/10/202421:05GlobeNewswire Inc.Tenax Therapeutics to Present at the Guggenheim Healthcare Innovation ConferenceNASDAQ:TENXTenax Therapeutics Inc
27/09/202414:14Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:TENXTenax Therapeutics Inc
13/09/202406:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:TENXTenax Therapeutics Inc
12/09/202422:15Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:TENXTenax Therapeutics Inc
30/08/202422:19Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:TENXTenax Therapeutics Inc
23/08/202422:31Edgar (US Regulatory)Form D - Notice of Exempt Offering of SecuritiesNASDAQ:TENXTenax Therapeutics Inc
06/08/202422:55AllPennyStocks.comBiotech Soars Following Oversubscribed $100M Private Placement AnnouncementNASDAQ:TENXTenax Therapeutics Inc
24/05/202422:31Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:TENXTenax Therapeutics Inc
14/05/202414:00GlobeNewswire Inc.Tenax Therapeutics Reports First Quarter 2024 Financial Results and Provides a Corporate UpdateNASDAQ:TENXTenax Therapeutics Inc
30/04/202413:30GlobeNewswire Inc.Tenax Therapeutics Announces New U.S. Patent Covering the Use of Levosimendan in Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF)NASDAQ:TENXTenax Therapeutics Inc
09/04/202414:30GlobeNewswire Inc.Tenax Therapeutics to Host KOL Event: “LEVEL Setting: the Scientific Rationale for Levosimendan as a Potential First Treatment for PH-HFpEF, and the Ongoing Phase 3 LEVEL Study”NASDAQ:TENXTenax Therapeutics Inc
28/03/202413:30GlobeNewswire Inc.Tenax Therapeutics Provides Business and Clinical Development Updates with Full Year 2023 Financial ResultsNASDAQ:TENXTenax Therapeutics Inc
12/03/202413:30GlobeNewswire Inc.Tenax Therapeutics to Present at the 36th Annual Roth ConferenceNASDAQ:TENXTenax Therapeutics Inc
29/02/202415:00GlobeNewswire Inc.Tenax Therapeutics Announces Oral Presentation of Levosimendan for the Treatment of PH-HFpEF at THT 2024NASDAQ:TENXTenax Therapeutics Inc
20/02/202422:01Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:TENXTenax Therapeutics Inc
20/02/202414:30GlobeNewswire Inc.Tenax Therapeutics Announces Global License Amendment that Significantly Expands Rights to LevosimendanNASDAQ:TENXTenax Therapeutics Inc
14/02/202420:58Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:TENXTenax Therapeutics Inc
09/02/202423:00Edgar (US Regulatory)Form 424B4 - Prospectus [Rule 424(b)(4)]NASDAQ:TENXTenax Therapeutics Inc
08/02/202414:16GlobeNewswire Inc.Tenax Therapeutics Announces Pricing of Approximately $9 Million Public OfferingNASDAQ:TENXTenax Therapeutics Inc
08/02/202402:01GlobeNewswire Inc.Tenax Therapeutics Enrolls First Patient in Phase 3 LEVEL Study Evaluating TNX-103 (Oral Levosimendan) for the Treatment of Pulmonary Hypertension in Heart Failure with Preserved Ejection Fraction (PH-HFpEF)NASDAQ:TENXTenax Therapeutics Inc
06/02/202414:30GlobeNewswire Inc.Tenax Therapeutics Announces USPTO Grants Notice of Allowance for U.S. Patent Application, Significantly Broadening IP Protection for Use of Levosimendan in Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF)NASDAQ:TENXTenax Therapeutics Inc
02/02/202423:24Edgar (US Regulatory)Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]NASDAQ:TENXTenax Therapeutics Inc
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:TENX

La tua Cronologia

BIT
ISP
Intesa Sanpaolo
BIT
UCG
Unicredit
BIT
ENI
Eni
BIT
STLAM
Stellantis NV
BIT
ENEL
Enel
BIT
BMPS
Banca Monte Dei Paschi D...
BIT
STMMI
ST Microelectronics
BIT
TIT
Telecom Italia
BIT
LDO
Leonardo
BIT
RACE
Ferrari NV
BIT
PRY
Prysmian
BIT
SPM
Saipem
BIT
BPE
Bper Banca
BIT
CPR
Davide Campari
BIT
AMP
Amplifon
BIT
SRG
Snam
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network